Literature DB >> 1102235

Duration of hydralazine action in hypertension.

K O'Malley, J L Segal, Z H Israili, M Boles, J L McNay, P G Dayton.   

Abstract

The effect on blood pressure of giving hydralazine orally, 300 mg per day divided into 2, 3, and 4 doses, was studied in 4 hypertensive patients. There was no significant difference in average mean arterial pressure for the 3 regimens. Fluctuations of mean arterial pressure with time were not significantly different for the regimens as indicated by coefficient of variation. The mean coefficient of variation for the 2 days prior to initiation of hydralazine dosing was 4.0% +/- 0.3 (SEM) and for the 3 dosing regimens ranged from 4.1% to 4.8%. Heart rate was used as an index of vasodilator-induced increase in sympathetic tone and therefore as a measure of possible side effects. Fluctuations in heart rate were small and were not associated with symptoms. After discontinuation of hydralazine, the time for blood pressure to return halfway between initial placebo value and end treatment value varied from 30 to 140 hr. A tracer dose of hydralazine 14C. HCl was administered intravenously to the patients. The urinary excretion of 14C showed a multiexponential pattern of elimination with a previously undescribed prolonged terminal phase. Under the conditions of the present study, a daily dose of 300 mg of hydralazine was as effective and free of side effects given in 2 as in 4 divided doses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1102235     DOI: 10.1002/cpt1975185part1581

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Hydralazine dose-response curve analysis.

Authors:  D A Graves; K T Muir; W Richards; B W Steiger; I Chang; B Patel
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

Review 2.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

3.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

4.  Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.

Authors:  Michelle F Gaynor; Garth C Wright; Sheryl Vondracek
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-01

Review 5.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

6.  Comparative evaluation of the in vitro effects of hydralazine and hydralazine acetonide on arterial smooth muscle.

Authors:  K Barron; O Carrier; K D Haegele; A J McLean; J L McNay; P Du Souich
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

7.  Hydralazine once daily in hypertension.

Authors:  J H Silas; L E Ramsay; S Freestone
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29

8.  Altered blood pressure response to propyldazine after repeated oral administration in conscious normotensive dogs: role of the renin-angiotensin system.

Authors:  S Bacher; O Kraupp; A Beck; R Seitelberger; G Raberger
Journal:  Basic Res Cardiol       Date:  1984 Sep-Oct       Impact factor: 17.165

9.  A comparison of nicardipine and labetalol for acute hypertension management following stroke.

Authors:  Xi Liu-Deryke; James Janisse; William M Coplin; Dennis Parker; Gregory Norris; Denise H Rhoney
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 10.  Treatment of acute severe hypertension: current and newer agents.

Authors:  Joseph Varon
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.